U.S. Navy Chooses Yellowbrick, Sunsets IBM Netezza
Yellowbrick selected for exemplary ease of migration, performance, and providing a pathway to the cloud…
Yellowbrick selected for exemplary ease of migration, performance, and providing a pathway to the cloud…
Company to host conference call to discuss financial results and provide a corporate update on…
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSXV: RKV) (“the…
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) — Preprint of results from animal study shows…
Patent provides intellectual property protection until December 2040 PH-HFpEF affects more than 1,600,000 North Americans, with…
Results from survey of Urea Cycle Disorders (UCD) healthcare providers show taste and odor were…
Patent developed in collaboration with Syngene International Ltd. MINNEAPOLIS, March 22, 2023 (GLOBE NEWSWIRE) —…
– Founding CEO, Axel Bolte, MSc, MBA, to retire; Douglas A. Treco, Ph.D., to succeed…
NEWTON, Mass., March 22, 2023 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that…
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated,…
– In NHP, four monthly doses of 20 mg/kg of PGN-EDO51 resulted in 34.9% exon…
BRIDGEWATER, N.J., March 22, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or…
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) — LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient…
Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution MORRISVILLE, N.C., March…
Achieved clinical validation of PRISM platform in 2022 – demonstrated ability to potently and durably…
ROCKVILLE, Md., March 22, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the…
Major progress in development of vilobelimab Phase III study in PG announced following detailed feedback…
TORONTO and CHICAGO, March 22, 2023 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals (TSX: MDP; OTCQX: MEDXF) is pleased…